Search the Newsreel

Insight Enterprises (NASDAQ:NSIT) Releases Earnings Results, Beats Expectations By $0.93 EPS

Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Intellect Design Arena expands pipeline to ₹13,000 Cr, clarifies Purple Fabric strategy

Paysign (NASDAQ:PAYS) Sees Large Volume Increase on Better-Than-Expected Earnings

Paysign (PAYS) Stock Jumps As Margin Strength Resets The Story

Inseego (Nasdaq: INSG) posts Q2 loss, details Nokia FWA acquisition and financing

SignatureGlobal India Q1 Results: Earnings Call Audio Released

Sight Sciences earnings beat by $0.07, revenue topped estimates

Is Insight Enterprises (NSIT) Quietly Redefining Its Margin Story With AI-Driven T&E Automation?

Insight Enterprises (NSIT) has partnered with Navan for AI-driven travel and expense management, aiming to improve efficiency and reallocate employee hours to higher-value work. This initiative supports Insight's strategy of shifting towards higher-margin, AI-enabled services and operational efficiency. The company's investment narrative projects significant …

Sight Sciences Sees Q2 Revenue Growth, Raises 2026 Guidance

Sight Sciences, Inc. reported strong financial results for Q2 2026, with revenue increasing by 20 percent to $23.4 million and a significant reduction in net loss. The company raised its full-year 2026 revenue guidance to $88 million to $92 million, driven by growth in …

Sight Sciences (NASDAQ:SGHT) Posts Earnings Results, Beats Estimates By $0.10 EPS

DOCU Stock News Today | Earnings, Events & Price Alerts

This article provides news and event updates for DocuSign (DOCU) stock, including recent market performance and upcoming events. It highlights DocuSign's partnership with Perplexity for enhanced contract management and its integration of AI into its intelligent agreement management platform. The article also touches on …

Earnings call transcript: Sight Sciences raises 2026 outlook on Q2 growth, shares fall

Sight Sciences reported a strong Q2 2026 with revenue increasing 20% year-over-year to $23.4 million, its fastest growth since 2023, and a narrowed net loss. The company raised its full-year 2026 revenue guidance to $88 million-$92 million and lowered adjusted operating expense guidance. Despite …

Paysign (NASDAQ:PAYS) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Sight Sciences, Inc. reports results for the quarter ended June 30 - Earnings Summary

Sight Sciences, Inc. has released its earnings summary for the quarter that ended on June 30. The report, provided by Refinitiv, gives an overview of the company's financial performance during this period.

RxSight Q2 FY26 net loss widens 2.6% to $12.1 million; revenue rises 0.3% to $33.7 million

RxSight reported a Q2 FY26 net loss of $12.1 million, a 2.6% increase, despite a 0.3% rise in revenue to $33.7 million. The revenue increase was primarily driven by a $6.5 million license fee, which offset a 19% decline in product sales. The company's …

Paysign Q2 2026 Earnings: Pharma Growth Drives 48% Revenue Increase

Paysign (NASDAQ: PAYS) reported a 48.1% year-over-year revenue increase to $28.25 million in Q2 2026, driven primarily by growth in pharma patient affordability programs. This shift towards higher-margin pharma revenue also led to significant margin expansion, with GAAP diluted EPS rising to $0.11 from …

Federal Signal Corp (NYSE: FSS) insider sells 19,264 shares

Diane Bonina, VP, General Counsel & Secretary of Federal Signal Corp (NYSE: FSS), exercised stock options for 14,856 shares and subsequently sold a total of 19,264 common shares in open-market transactions on August 3-4, 2026. The sales generated approximately $2.51 million in gross proceeds. …

PAYS: Record revenue, margin expansion, and raised outlook driven by Patient Affordability growth

Paysign, Inc. (PAYS) reported record Q2 results, with 48% revenue growth and a 113% increase in adjusted EBITDA, primarily due to Patient Affordability and plasma recovery. The company raised its full-year guidance, expanded margins, and demonstrated platform scalability. This positive performance was highlighted during …

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) reported a Q2 loss of $0.08 per share, outperforming the Zacks Consensus Estimate of a $0.15 loss, and significantly improving from a $0.23 loss a year ago. The company also surpassed revenue estimates, posting $23.39 million against an anticipated $21.75 …

Sigma Lithium Corporation (SGML) Dips More Than Broader Market: What You Should Know

Sigma Lithium Corporation (SGML) experienced a 4.95% dip, underperforming the broader S&P 500, which only saw a 0.17% loss. Despite recent monthly losses for its shares, analysts project significant earnings and revenue growth for the company's upcoming disclosures, with an anticipated 188.24% EPS increase …

RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

RxSight, Inc. (RXST) reported a narrower-than-expected Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.21 loss, and surpassed revenue estimates with $33.74 million. Despite beating estimates, the company's shares have fallen 40% year-to-date, while the broader S&P 500 gained …

VeriSign (VRSN) Could Be 81% Above Fair Value On Raised Guidance And Buybacks

VeriSign (VRSN) has seen a significant share price increase following strong Q2 2026 earnings, updated guidance, increased share repurchases, and a new dividend. Despite this positive momentum, a widely followed narrative suggests the stock is 81% overvalued due to reliance on its .com and …

PaySign Inc (PAYS) (Q2 2026) Earnings Call Highlights: Record Revenue Surges 48% as Patient ...

PaySign Inc (PAYS) reported record second-quarter 2026 results, with total revenue surging 48.1% year-over-year to $28.3 million, driven primarily by an 88.9% increase in Pharma Revenue to $14.6 million. Net income saw a nearly five-fold increase to $6.8 million, and adjusted EBITDA rose by …

Earnings call transcript: Paysign tops Q2 2026 estimates and lifts outlook

Paysign Inc. reported strong second-quarter 2026 results, surpassing Wall Street's earnings and revenue estimates and leading to a raised full-year outlook. The company's performance was significantly driven by its patient affordability programs, which saw an 89% increase in revenue, and a recovery in its …

Earnings call transcript: RxSight beats Q2 2026 estimates but withdraws guidance

RxSight reported better-than-expected Q2 2026 earnings and revenue, but its stock fell after the company withdrew its full-year guidance due to ongoing pressure in its core business. The ophthalmology company's adjusted EPS beat estimates by $0.25, and revenue topped forecasts, partly aided by a …

D James Bidzos Sells 3,300 Shares of VeriSign (NASDAQ:VRSN) Stock

VeriSign CEO D. James Bidzos sold 3,300 shares of VeriSign (NASDAQ:VRSN) stock on August 4th for $978,582, reducing his stake by 0.8% to 409,639 shares. This transaction, part of a Rule 10b5-1 plan, follows several other sales by Bidzos in recent months. The company …

RxSight (RXST) Stock Falls on Q2 2026 Earnings

RxSight Inc (NASDAQ:RXST) is scheduled to release its Q2 2026 earnings on August 7, 2026, with revenue expected at $32.55 million and earnings at $-0.32 per share. GuruFocus estimates a significant upside of 518.60% for RXST based on its GF Value of $38.91, despite …

Keysight Technologies Inc. stock underperforms Wednesday when compared to competitors

Keysight Technologies Inc. (KEYS) stock fell by 1.53% on Wednesday, closing at $336.02. This decline occurred despite a mixed trading session where the Dow Jones Industrial Average rose, while the S&P 500 Index decreased. The stock's underperformance ended a four-day winning streak for the …

Sigma Lithium to Release 2Q 26 Earnings Results on Aug 14; Exceeded 1H 26 Production Target

Sigma Lithium Corporation announced it will release its second quarter 2026 earnings results on August 14, 2026, after exceeding its 1H 2026 production target by 6%, delivering 35,000 tonnes of high-grade lithium concentrate in Q2 and 58,000 tonnes in 1H. The company, the largest …

Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook

Paysign, Inc. reported record second-quarter 2026 revenue of $28.3 million, a 48% increase year-over-year, driven by significant growth in its pharma patient affordability business (up 88.9%) and steady performance in plasma revenue (up 21.4%). The company also saw its GAAP net income increase by …

VeriSign (NASDAQ: VRSN) CEO sells 3,300 shares under Rule 10b5-1 plan

VeriSign Inc. CEO D. James Bidzos sold a total of 3,300 shares of common stock on August 4, 2026, under a Rule 10b5-1 trading plan. The sales occurred in five separate transactions at weighted average prices ranging from $294.4750 to $299.4700 per share. Following …

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences reported strong second-quarter 2026 financial results, with total revenue increasing by 20% year-over-year to $23.4 million, driven by significant growth in Interventional Dry Eye revenue (704% increase). The company raised its full-year 2026 revenue guidance to $88 million to $92 million and …

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

RxSight, Inc. reported its financial results for the second quarter of 2026, with total revenue reaching $33.7 million, including $6.5 million from its collaboration with Alcon. The company also announced key strategic developments, such as the appointment of Aziz Mottiwala as CEO and a …

RxSight, Inc. (RXST) Tops Q2 EPS by 25c

RxSight, Inc. (NASDAQ: RXST) reported strong financial results for Q2, with earnings per share of ($0.11), significantly surpassing analyst estimates of ($0.36) by $0.25. The company's revenue also exceeded expectations, coming in at $33.74 million against a consensus estimate of $32.21 million.

Aetna covers Sight Sciences glaucoma devices for commercial plans By Investing.com

Aetna Inc. has updated its Glaucoma Surgery Policy for commercial plans to recognize Sight Sciences' OMNI Surgical System and SION Surgical Instrument as medically necessary for treating mild-to-moderate open-angle glaucoma. This coverage, retroactive to July 14, 2026, applies to approximately 25 million Aetna commercial …